Shanghai Pharmaceuticals Holding Co Ltd

Shanghai Pharmaceuticals Holding Co., Ltd.(hereinafter as Shanghai Pharma, SSE stock code 601607 and HKEx stock code 02607)  is a large pharmaceutical group to have a dual-listing in the stock exchanges of Shanghai and Hong Kong. The Company's core business covers pharmaceutical R&D, manufacturing, distribution and retailing. In 2016, the Company reported a total revenue of  RMB 120.8 billion, making it one of the major forces in the industry in China. The Company is the one of the few listed pharmaceutical companies which holds a leading position in both pharmaceutical manufacturing and distribution in China. It is selected into the sample stocks of the SSE 180 Index, CSI 300 Index, Hang Seng Index Compositional Stocks and MSCI.

Shanghai Pharma's Research and development is dedicated to providing innovative, safe and effective drugs against serious and chronic diseases. The total amount of R&D investment of the Company was accounting for 5.40% of manufacturing sales.The Company has built up the R&D systems with the Central Research Institute acting as the technical core. The Company owns 1 State-level corporate technology center and 10 provincial/city-level corporate technology centers. Shanghai Pharma has registered 319 invention patents in total. Two cooperative projects won "the First-class National Scientific and Technological Progress Award of 2014 and 2015". The Company adopts an open mode of R&D, under which the Company has built up the strategic alliance of innovative drug R&D in collaboration with Shanghai Institute of Materia Medica, China Pharmaceutical University ,Shenyang Pharmaceutical University, Mitsubishi Tanabe Pharma Corporation, the Second Military Medical  University, Shanghai Fudan Zhangjiang Biopharm etc. Many innovative products are in the registration or clinical trial stages.

Shanghai Pharma's manufacturing business provides products ranging from chemical and bio-pharms, modern Chinese medicine, healthcare products and medical devices etc., Shanghai Pharmaceuticals is focused on five therapeutic areas of digestive systems and metabolism , cerebral and cardio vascular diseases, antoinfection, neuro-psycho diseases and oncology. It has manufacturing bases in 8 provinces, including a specialist API base, a modern TCM (Traditional Chinese Medicine) base, a fine chemical reagent factory and a health care products production base. The products are made in over 20 dosage forms, 26 products have annual sales revenues over RMB 100 million. The Company runs a number of brands, such as SINE, Leishi, Dragon & Tiger, Cangsong, Guofeng and Shengxiang, all of which are the renowned Chinese trademarks, and is authorized to use the well-known trademarks of Qingchunbao and Huqingyutang. All our production lines have passed the new GMP certification, The company has implemented the lean management system, optimized production and conducted pilot programs to integrate information technology and industrialization. A number of our APIs and preparations have passed quality authentication from the WHO, FDA, EU and other developed countries.

Shanghai Pharma's distribution network covers the whole Chinese territory, starting with the most developed regions (Eastern, Northern and Southern parts) and expanding to other areas. Our distribution system is the third largest in size nationwide. The Company established a close cooperation relationship with domestic and foreign major drug manufacturers through supply chain solutions such as modern logistics delivery, information support and terminal retail distribution. It covers more than 27,000 healthcare institutions. The Company has a nationwide commercial network and an efficient, agile, smart and modern supply chain service channel. SPH is the leader in new business development for vaccines, high-end consumables, DTP and SPD in China.

Shanghai Pharma is one of the top pharmaceutical retailers in China in terms of sales revenue. Our Huashi Pharmacy is one of the largest drugstore chains in Eastern China with about 1800 locations covering 16 provinces, autonomous regions and municipalities. he retailing business of Shanghai Pharma includes diversified business models, comprising the chain drugstores, joint-venture drugstores and DTP drugstores etc. We carry out the in-depth integration of internal retail resources using "Huashi" as the platform and  modern information technology as the carrier to expand Tmall store, remote video pharmic counseling, medicine retail network, self-help medicine-purchasing machine and other new health service models. The company is exploring the new pharmaceutical business mode, SPH Health Cloud cooperated with Jingdong, Wanda, DXY etc., providing service platform to focus on consumer experience and more professional services, more convenient ways for drug purchase and more comprehensive health management.

With a solid foundation anchored in our core values – innovation, integrity, cooperation, inclusiveness and responsibility – Shanghai Pharma is continuously dedicated to the providing a healthier life to the general public, while striving to be recognized as a respected manufacturer of leading pharmaceutical brands, as well as a healthcare services provider with a stellar reputation.

Telephone：(0086 21)6373 0908